Pfizer set low expectations for the trial, due to recruitment requirements for the age range and lower infection rates. They are starting with the oldest cohort (9-12) and work their way down.

I expect the 12-15 age group to be authorized under EUA by end of Q2 and the under 12 age group by late Q4.